Compare GRML & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | GRML | RAND |
|---|---|---|
| Founded | N/A | 1969 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Finance: Consumer Services |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.2M | 29.9M |
| IPO Year | 2022 | 1996 |
| Metric | GRML | RAND |
|---|---|---|
| Price | $0.21 | $10.14 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 7.2M | 1.9K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 10.83% |
| EPS Growth | ★ 31.25 | N/A |
| EPS | N/A | ★ 0.34 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $30.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $10.00 |
| 52 Week High | $0.55 | $17.49 |
| Indicator | GRML | RAND |
|---|---|---|
| Relative Strength Index (RSI) | 47.25 | 51.63 |
| Support Level | $0.17 | $10.02 |
| Resistance Level | $0.30 | $10.49 |
| Average True Range (ATR) | 0.02 | 0.09 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 53.14 | 65.79 |
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. Its investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.